Myllia Biotechnology

Enabling Single-Cell Drug Discovery

Myllia Biotechnology (former Aelian Biotechnology) combines CRISPR screening with single-cell sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes.

We use the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next-generation CRISPR screens.

Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions of drugs.